Aurora Cannabis (TSE:ACB) Price Target Cut to C$8.00 by Analysts at TD

Aurora Cannabis (TSE:ACB) had its price objective cut by stock analysts at TD to C$8.00 in a research report issued on Friday,BayStreet.CA reports. The brokerage presently has a “buy” rating on the stock. TD’s price target indicates a potential upside of 88.24% from the company’s current price.

Aurora Cannabis Stock Down 0.7%

TSE ACB traded down C$0.03 during midday trading on Friday, hitting C$4.25. 371,398 shares of the company traded hands, compared to its average volume of 412,147. The company has a debt-to-equity ratio of 25.02, a current ratio of 3.06 and a quick ratio of 2.48. The company has a market cap of C$251.29 million, a PE ratio of -2.83 and a beta of 0.17. The company’s 50-day simple moving average is C$4.77 and its 200-day simple moving average is C$5.31. Aurora Cannabis has a 52 week low of C$3.77 and a 52 week high of C$9.33.

Aurora Cannabis (TSE:ACB) last announced its earnings results on Thursday, June 11th. The company reported C($0.99) earnings per share (EPS) for the quarter. Aurora Cannabis had a negative net margin of 1.69% and a negative return on equity of 1.15%. The company had revenue of C$38.01 million for the quarter. As a group, equities research analysts forecast that Aurora Cannabis will post -0.22 earnings per share for the current year.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.